CHARLOTTESVILLE, Virginia, December 16 -- Biovista Inc. today announced that it was awarded the 2009 Top Innovator PresentationAward in Healthcare, at the 2009 New England Venture Summit, held on December 8th at Dedham, MA. The award, which recognizes cutting edge private companies driving the future of innovation,
"We are honored to have been selected as the winner amongst this elite group of companies," said Dr. Aris Persidis, Biovista Inc. President, who presented at the Summit. "I believe that the award reflects the emerging importance of Drug Repositioning and Adverse Event profiling, and their potential to dramatically increase the efficiency and safety of drug development," added Dr. Persidis.
About Biovista's repositioning pipeline and technology platform
Biovista applies high-throughput discovery efforts to finding solutions for commercially relevant unmet medical needs. Biovista's proprietary repositioning technology allows the company's experts to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and very short time spans. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and auto-immune diseases.
About the New England Venture Summit
The New England Venture Summit is an annual invitation-only event, where a select group of over 450 entrepreneurs, investors, and corporate developers gather to meet early stage and emerging growth companies, and to share their insights on the future of innovation.
For more information, please contact: Dr. Aris Persidis Biovista, Inc. +1-434-242-6514 firstname.lastname@example.org
SOURCE Biovista Inc.
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All